Trials / Withdrawn
WithdrawnNCT03747328
ABI-009 (Nab-sirolimus) in Patients With Genetically-confirmed Leigh or Leigh-like Syndrome
A Phase 2a, Open-label Study to Evaluate the Safety, Tolerability, and Clinical Activity of ABI-009 (Nab-sirolimus) in Patients With Genetically-confirmed Leigh or Leigh-like Syndrome
- Status
- Withdrawn
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 0 (actual)
- Sponsor
- Aadi Bioscience, Inc. · Industry
- Sex
- All
- Age
- 2 Years – 17 Years
- Healthy volunteers
- Not accepted
Summary
A phase 2a, open-label study to evaluate the safety, tolerability, and clinical activity of ABI-009 (nab-sirolimus) in patients with genetically-confirmed Leigh or Leigh-like syndrome
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | ABI-009 | nanoparticle albumin bound sirolimus |
Timeline
- Start date
- 2022-04-30
- Primary completion
- 2024-12-31
- Completion
- 2025-03-31
- First posted
- 2018-11-20
- Last updated
- 2022-02-01
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT03747328. Inclusion in this directory is not an endorsement.